TY - JOUR
T1 - The burden of pneumococcal disease
T2 - The role of conjugate vaccines
AU - Poland, Gregory A.
N1 - Funding Information:
I would like to acknowledge the efforts of the many nurses, fellows, technicians and students from the Mayo Vaccine Research Group. GAP is supported by Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, under contract number NO1-AI-45240 and RO1-2AI-33144. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government.
PY - 1999/1
Y1 - 1999/1
N2 - The pneumococcus remains a major cause of morbidity and mortality in both underdeveloped and developed countries. Although there are licensed, safe vaccines against invasive pneumococcal disease currently available in the US and Europe, several major dilemmas are apparent. First, the efficacy of these vaccines in high risk immunocompetent adults is only moderate, with limited or no immunogenicity in very high risk, immunocompromised adults. Secondly, efficacy of the vaccine against pneumococcal pneumonia in adults is controversial. Thirdly, the current vaccines are not efficacious in children < 2 years of age, which is problematic given the high rate of invasive disease among this age group. The solution to these dilemmas may lie in the development of protein conjugate-polysaccharide vaccines. This paper briefly reviews the role of conjugate pneumococcal vaccines.
AB - The pneumococcus remains a major cause of morbidity and mortality in both underdeveloped and developed countries. Although there are licensed, safe vaccines against invasive pneumococcal disease currently available in the US and Europe, several major dilemmas are apparent. First, the efficacy of these vaccines in high risk immunocompetent adults is only moderate, with limited or no immunogenicity in very high risk, immunocompromised adults. Secondly, efficacy of the vaccine against pneumococcal pneumonia in adults is controversial. Thirdly, the current vaccines are not efficacious in children < 2 years of age, which is problematic given the high rate of invasive disease among this age group. The solution to these dilemmas may lie in the development of protein conjugate-polysaccharide vaccines. This paper briefly reviews the role of conjugate pneumococcal vaccines.
KW - Pneumococcal vaccine
KW - Protein conjugate
UR - http://www.scopus.com/inward/record.url?scp=0344267653&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0344267653&partnerID=8YFLogxK
U2 - 10.1016/S0264-410X(98)00435-6
DO - 10.1016/S0264-410X(98)00435-6
M3 - Article
C2 - 10194822
AN - SCOPUS:0344267653
SN - 0264-410X
VL - 17
SP - 1674
EP - 1679
JO - Vaccine
JF - Vaccine
IS - 13-14
ER -